Search research articles
Contact Us
Filters
Showing results (171-180 of 308) with videos related to
Page
of 31
Sort By:
Tomography (Ann Arbor, Mich.)
|
June 18, 2020
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
Alex Anh-Tu Nguyen, Vignesh A Arasu, Fredrik Strand, et al.
Journal of Breast Imaging
|
August 18, 2020
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients
Vignesh A Arasu, Paul Kim, Wen Li, et al.
NPJ Breast Cancer
|
October 26, 2021
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
Mary Kathryn Abel, Michelle E Melisko, Hope S Rugo, et al.
Tomography (Ann Arbor, Mich.)
|
June 18, 2020
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
Natsuko Onishi, Wen Li, Jessica Gibbs, et al.
Breast Cancer Research and Treatment
|
July 29, 2011
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
Cheryl Lin, Meredith Becker Buxton, Dan Moore, et al.
Journal of the American College of Surgeons
|
February 3, 2009
Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
Liang-Chih Liu, Julie E Lang, Tyler Jenkins, et al.
Nature Methods
|
April 1, 2009
The UCSC Cancer Genomics Browser
Jingchun Zhu, J Zachary Sanborn, Stephen Benz, et al.
NPJ Breast Cancer
|
April 25, 2019
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
Ella F Jones, Kimberly M Ray, Wen Li, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
April 27, 2019
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL
Wen Li, David C Newitt, Lisa J Wilmes, et al.
JAMA Oncology
|
January 17, 2025
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial
Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, et al.
Page
of 31
Search research articles
Search
Showing results (171-180 of 308) with videos related to
Sort By:
Page
of 31
Tomography (Ann Arbor, Mich.)
|
June 18, 2020
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
Alex Anh-Tu Nguyen, Vignesh A Arasu, Fredrik Strand, et al.
Journal of Breast Imaging
|
August 18, 2020
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients
Vignesh A Arasu, Paul Kim, Wen Li, et al.
NPJ Breast Cancer
|
October 26, 2021
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
Mary Kathryn Abel, Michelle E Melisko, Hope S Rugo, et al.
Tomography (Ann Arbor, Mich.)
|
June 18, 2020
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
Natsuko Onishi, Wen Li, Jessica Gibbs, et al.
Breast Cancer Research and Treatment
|
July 29, 2011
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
Cheryl Lin, Meredith Becker Buxton, Dan Moore, et al.
Journal of the American College of Surgeons
|
February 3, 2009
Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
Liang-Chih Liu, Julie E Lang, Tyler Jenkins, et al.
Nature Methods
|
April 1, 2009
The UCSC Cancer Genomics Browser
Jingchun Zhu, J Zachary Sanborn, Stephen Benz, et al.
NPJ Breast Cancer
|
April 25, 2019
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
Ella F Jones, Kimberly M Ray, Wen Li, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
April 27, 2019
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL
Wen Li, David C Newitt, Lisa J Wilmes, et al.
JAMA Oncology
|
January 17, 2025
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial
Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, et al.
Page
of 31